These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 16361855)

  • 1. A nexus of progression of chronic kidney disease: charcoal, tryptophan and profibrotic cytokines.
    Schulman G
    Blood Purif; 2006; 24(1):143-8. PubMed ID: 16361855
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A nexus of progression of chronic kidney disease: tryptophan, profibrotic cytokines, and charcoal.
    Schulman G
    J Ren Nutr; 2012 Jan; 22(1):107-13. PubMed ID: 22200426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The protein metabolite hypothesis, a model for the progression of renal failure: an oral adsorbent lowers indoxyl sulfate levels in undialyzed uremic patients.
    Niwa T; Nomura T; Sugiyama S; Miyazaki T; Tsukushi S; Tsutsui S
    Kidney Int Suppl; 1997 Nov; 62():S23-8. PubMed ID: 9350673
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Indoxyl sulfate-lowering capacity of oral sorbents affects the prognosis of kidney function and oxidative stress in chronic kidney disease.
    Taki K; Niwa T
    J Ren Nutr; 2007 Jan; 17(1):48-52. PubMed ID: 17198932
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oral charcoal adsorbent (AST-120) prevents progression of cardiac damage in chronic kidney disease through suppression of oxidative stress.
    Fujii H; Nishijima F; Goto S; Sugano M; Yamato H; Kitazawa R; Kitazawa S; Fukagawa M
    Nephrol Dial Transplant; 2009 Jul; 24(7):2089-95. PubMed ID: 19188341
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Indoxyl sulfate induces nephrovascular senescence.
    Niwa T; Shimizu H
    J Ren Nutr; 2012 Jan; 22(1):102-6. PubMed ID: 22200425
    [TBL] [Abstract][Full Text] [Related]  

  • 7. AST-120 ameliorates epithelial-to-mesenchymal transition and interstitial fibrosis in the kidneys of chronic kidney disease rats.
    Bolati D; Shimizu H; Niwa T
    J Ren Nutr; 2012 Jan; 22(1):176-80. PubMed ID: 22200438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, randomized, double-blind, placebo-controlled, dose-ranging study of AST-120 (Kremezin) in patients with moderate to severe CKD.
    Schulman G; Agarwal R; Acharya M; Berl T; Blumenthal S; Kopyt N
    Am J Kidney Dis; 2006 Apr; 47(4):565-77. PubMed ID: 16564934
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of repeated oral administrations of the oral adsorbent AST-120 on serum creatinine and other markers of renal function. A randomized controlled study in patients with chronic kidney disease.
    Marier JF; Lee J; Kambhampati SR; Galitz L; Vargas R; Moberly J; Salazar DE
    Am J Nephrol; 2006; 26(2):136-41. PubMed ID: 16549905
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of the oral adsorbent AST-120 on tryptophan metabolism in uremic patients.
    Tsubakihara Y; Takabatake Y; Oka K; Shoji T; Togawa M; Okada N; Takahito I; Imai E
    Am J Kidney Dis; 2003 Mar; 41(3 Suppl 1):S38-41. PubMed ID: 12612950
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effect of a carbonaceous oral adsorbent on the progression of CKD: a multicenter, randomized, controlled trial.
    Akizawa T; Asano Y; Morita S; Wakita T; Onishi Y; Fukuhara S; Gejyo F; Matsuo S; Yorioka N; Kurokawa K;
    Am J Kidney Dis; 2009 Sep; 54(3):459-67. PubMed ID: 19615804
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Indoxyl sulfate is a nephro-vascular toxin.
    Niwa T
    J Ren Nutr; 2010 Sep; 20(5 Suppl):S2-6. PubMed ID: 20797565
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective randomized study evaluating the efficacy of the spherical adsorptive carbon AST-120 in chronic kidney disease patients with moderate decrease in renal function.
    Shoji T; Wada A; Inoue K; Hayashi D; Tomida K; Furumatsu Y; Kaneko T; Okada N; Fukuhara Y; Imai E; Tsubakihara Y
    Nephron Clin Pract; 2007; 105(3):c99-107. PubMed ID: 17179734
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Effect of oral sorbent, AST-120, on serum concentration of indoxyl sulfate in uremic rats].
    Niwa T; Yazawa T; Maeda K; Ise M; Sugano M; Kodama T; Uehara Y
    Nihon Jinzo Gakkai Shi; 1990 Jun; 32(6):695-701. PubMed ID: 2120492
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Serum indoxyl sulfate is a useful predictor for progression of chronic kidney disease].
    Namba S; Okuda Y; Morimoto A; Kojima T; Morita T
    Rinsho Byori; 2010 May; 58(5):448-53. PubMed ID: 20560454
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of indoxyl sulfate in the progression of chronic kidney disease and cardiovascular disease: experimental and clinical effects of oral sorbent AST-120.
    Niwa T
    Ther Apher Dial; 2011 Apr; 15(2):120-4. PubMed ID: 21426500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of the oral adsorbent AST-120 versus placebo for chronic kidney disease.
    Takahashi T; Reed SD; Schulman KA
    Nephrology (Carlton); 2008 Oct; 13(5):419-27. PubMed ID: 18518936
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Role of oxidative stress and indoxyl sulfate in progression of cardiovascular disease in chronic kidney disease.
    Fujii H; Nakai K; Fukagawa M
    Ther Apher Dial; 2011 Apr; 15(2):125-8. PubMed ID: 21426501
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of oral adsorbent AST-120 under standard treatment of care in patients with chronic renal failure].
    Yoshida I; Komada T; Sakuma Y; Mori H; Funayama I; Tabei K
    Nihon Jinzo Gakkai Shi; 2009; 51(2):121-9. PubMed ID: 19378798
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeting protein-bound uremic toxins in chronic kidney disease.
    Niwa T
    Expert Opin Ther Targets; 2013 Nov; 17(11):1287-301. PubMed ID: 23941498
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.